# Dechra Pharmaceuticals PLC   Trading Update

- Link: https://www.directorstalkinterviews.com/dechra-pharmaceuticals-plc-trading-update/412787295
- Published: 2019-07-09T07:33:47+01:00
- Author: Amilia Stone

The Board of **Dechra Pharmaceutical PLC** (LON:DPH) issued the following unaudited
Trading Update covering the Group’s financial year ended 30 June 2019 (the Period)
ahead of the announcement of its preliminary financial results.

**Highlights**

 * Trading in the year was strong and in line with management expectations
 * Reported Group revenue for the Period increased by _c._17% at constant exchange
   rate (CER) (_c._18% at actual exchange rate (AER))
 * European Pharmaceuticals revenue growth was _c._18% at CER (AER _c_.17%)
 * North America Pharmaceuticals revenue growth was _c_.15% at CER (AER _c_.20%)
 * Completed the acquisitions of Caledonian in New Zealand and Australia and Laboratorios
   Vencofarma Brasil Ltda (Venco) in Brazil
 * Increased investment in Medical Ethics Pty Limited from 33% to 48% post year 
   end

> **Ian Page, Chief Executive Officer, said**:
> “We are pleased to have delivered another year of strong revenue growth. This 
> has been driven from our core portfolio, good market penetration and realisation
> of significant Le Vet revenue synergies. In addition the newly acquired Caledonian
> and Venco businesses have performed well.”

**Operational Review**

_European Pharmaceuticals_

In the Period, our European Pharmaceuticals segment reported revenue increased by
_c._18% at CER (17% at AER). Excluding third party contract manufacturing, treating
RX Vet and AST Farma/Le Vet on a like for like basis, and excluding the acquisitions
of Caledonian and Venco, revenues increased by _c._7% at CER (_c._7% at AER).  This
was achieved through the robust performance of our core business with FAP growth
accelerating and through the realisation of significant synergies from Le Vet.

The integration of AST Farma/Le Vet, Caledonian and Venco, is proceeding well and
trading is in line with expectations.

_North American Pharmaceuticals_

In the Period, our North American segment reported revenue increased by _c._15% 
at CER (_c._20% at AER). This was driven by our companion animal portfolio (CAP)
and represents strong outperformance of the market.

**Notice of Results**

Dechra will announce its Preliminary Results for the Period on Monday, 2 September
2019.

Share on:
